Precision dosing for inflammatory bowel disease medicines
Part of Digestive system clinical trials.
This study tests whether measuring drug levels in the blood can help doctors find the best dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for people with ulcerative colitis or Crohn's disease. It aims to improve control of these conditions while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with ulcerative colitis or Crohn's disease for at least 3 months.
- You have been on the same biologic medicine (vedolizumab or ustekinumab) for at least 3 months.
- Your disease is stable or only mildly active, and you haven't changed other IBD medications in the last 3 months.
- You do not have a stoma, pouch, or fistulizing disease as the main reason for treatment.
- You are not pregnant or nursing, and have no active serious infections or contraindications to your current biologic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
This study compares two biologic medicines, vedolizumab and infliximab, to see which works better for children with moderate to severe ulcerative colitis. It aims to find a more effective treatment to reduce symptoms and improve quality of life.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.